Annovis says ‘data cleaning’ postpones buntanetap readout in Parkinson’s

Annovis Bio has announced that the Phase III readout for their Parkinson's disease therapy, buntanetap (ANVS401), has been postponed due to "ongoing data cleaning" efforts. The company had previously expected the data to be published at the end of January 2024. Although no specific date has been provided for when the data will be available, Annovis emphasizes that their focus is on delivering trustworthy results and working hard to provide them soon.

The study, which was launched in the U.S. and Europe in August 2022, included a total of 616 patients, with 471 completing the trial. The trial involved administering either 10 mg or 20 mg of buntanetap to participants. Annovis ended September with cash and equivalents of $6.4 million, having spent $13.8 million in R&D costs over the third quarter, mostly on its late-stage buntanetap trials for Parkinson's and Alzheimer's.